Chimeric Antigen Receptor T-cell Therapy (CAR-T): Insights into Clinical Efficacy, Emerging Perspectives, and Future Innovations in Hematology Malignancies Treatment.: Review Article

malika salhi

doi:10.58372/2835-6276.1244

Authors

malika salhi UNIVERSITE PARIS CITE https://orcid.org/0009-0005-9200-327X

DOI:

https://doi.org/10.58372/2835-6276.1244

Keywords:

Chimeric antigen receptors (CARs), Hematology malignancies, Adoptive cell transfer, Immune checkpoint inhibitors, Bispecific, Biomarkers

Abstract

Chimeric antigen receptor (CAR) T-cell therapy has improved the outcome for patients with hematological malignancies. FDA-approved CAR-T-cell medications, such as tisagenlecleucel and axicabtagene ciloleucel, have significantly increased overall survival (OS) and progression-free survival (PFS) in patients with relapsed or refractory B-cell malignancies, particularly in pediatric acute lymphoblastic leukemia and diffuse large B-cell lymphoma. However, challenges remain, in particular in translating these successes to solid tumors, owing to issues such as tumor antigen heterogeneity, the immunosuppressive tumor microenvironment and antigen escape. Efforts to improve CAR-T-cell efficacy include exploring dual-target CAR constructs and combining CAR-T cells with radiotherapy, chemotherapy, or immunomodulatory agents. Additionally, the high costs of complex manufacturing processes and side effects, including cytokine release syndrome and neurotoxicity, remain significant issues. Research efforts are now focused on optimizing CAR-T-cell design, improving patient accessibility, and identifying biomarkers to predict patient outcomes. The use of real-world evidence and advanced computational modeling further highlights the important future role of CAR-T-cell therapy in cancer treatment. Overall, CAR-T-cell therapy has improved the outcomes of patients with hematologic malignancies and has potential for use in solid tumor therapy.

References

Han D, Xu Z, Zhuang Y, Ye Z, Qian Q. Current Progress in CAR-T Cell Therapy for Hematological Malignancies. Journal of Cancer. 2021;12(2):326-34.

Petty AJ, Heyman B, Yang Y. Chimeric Antigen Receptor Cell Therapy: Overcoming Obstacles to Battle Cancer. Cancers. 2020;12(4):842.

Guo F, Cui J. CAR-T in Cancer Treatment: Develop in Self-Optimization, Win-Win in Cooperation. Cancers. 2021;13(8):1955.

Fucà G, Reppel L, Landoni E, Savoldo B, Dotti G. Enhancing Chimeric Antigen Receptor T-Cell Efficacy in Solid Tumors. Clinical Cancer Research. 2020;26(11):2444-51.

Boulch M, Cazaux M, Loe-Mie Y, Thibaut R, Corre B, Lemaı̂tre F, et al. A Cross-Talk Between CAR T Cell Subsets and the Tumor Microenvironment Is Essential for Sustained Cytotoxic Activity. Science Immunology. 2021;6(57).

Alizadeh D, Wong RA, Gholamin S, Maker M, Aftabizadeh M, Yang X, et al. IFNγ Is Critical for CAR T Cell–Mediated Myeloid Activation and Induction of Endogenous Immunity. Cancer Discovery. 2021;11(9):2248-65.

Hegde M, Joseph S, Pashankar F, DeRenzo C, Sanber K, Navai SA, et al. Tumor Response and Endogenous Immune Reactivity After Administration of HER2 CAR T Cells in a Child With Metastatic Rhabdomyosarcoma. Nature Communications. 2020;11(1).

Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 2022;22(2):85-96.

Avanzi MP, Yeku O, Li X, Wijewarnasuriya D, Leeuwen DGv, Cheung K, et al. Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and Through Activation of the Endogenous Immune System. Cell Reports. 2018;23(7):2130-41.

Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management. Blood Rev. 2019;34:45-55.

Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018;378(5):439-48.

Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2019;380(1):45-56.

Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017;377(26):2531-44.

Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med. 2020;382(14):1331-42.

Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839-52.

Munshi NC, Anderson LD, Jr., Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2021;384(8):705-16.

Lin Y, Martin TG, Usmani SZ, Berdeja JG, Jakubowiak AJ, Agha ME, et al. CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma. Journal of Clinical Oncology. 2023;41(16_suppl):8009-.

Martin T, Usmani SZ, Berdeja JG, Agha M, Cohen AD, Hari P, et al. Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. J Clin Oncol. 2023;41(6):1265-74.

Zhang Q. Quartic CAR-T Cell Bridging to Twice Allo-HSCT Therapy in a Patient With Acute Lymphoblastic Leukemia. Transfusion Medicine and Hemotherapy. 2023;51(1):55-60.

Dorff TB, Blanchard MS, Adkins LN, Luebbert L, Leggett N, Shishido SN, et al. PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat Med. 2024;30(6):1636-44.

Majzner RG, Ramakrishna S, Yeom KW, Patel S, Chinnasamy H, Schultz L, et al. GD2-CAR T Cell Therapy for H3k27m-Mutated Diffuse Midline Gliomas. Nature. 2022;603(7903):934-41.

Bufalo FD, Angelis BD, Caruana I, Baldo GD, Ioris MAD, Serra A, et al. GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma. New England Journal of Medicine. 2023;388(14):1284-95.

Qi C, Gong J, Li J, Liú D, Qin Y, Ge S, et al. Claudin18.2-specific CAR T Cells in Gastrointestinal Cancers: Phase 1 Trial Interim Results. Nature Medicine. 2022;28(6):1189-98.

Zhang Q, Zhang Z, Liu G, Li D, Gu Z, Zhang L, et al. B7-H3 Targeted CAR-T Cells Show Highly Efficient Anti-Tumor Function Against Osteosarcoma Both in Vitro and in Vivo. BMC Cancer. 2022;22(1).

Pal SK, Tran B, Haanen J, Hurwitz ME, Sacher A, Tannir NM, et al. CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma. Cancer Discov. 2024;14(7):1176-89.

Tian M, Cheuk A, Wei JS, Abdelmaksoud A, Chou H-C, Milewski D, et al. An Optimized Bicistronic Chimeric Antigen Receptor Against GPC2 or CD276 Overcomes Heterogeneous Expression in Neuroblastoma. Journal of Clinical Investigation. 2022;132(16).

Watanabe K, Luo Y, Da T, Guedan S, Ruella M, Scholler J, et al. Pancreatic Cancer Therapy With Combined Mesothelin-Redirected Chimeric Antigen Receptor T Cells and Cytokine-Armed Oncolytic Adenoviruses. Jci Insight. 2018;3(7).

León-Triana O, Pérez‐Martínez A, Ramírez-Orellana M, Pérez-Garcı́a VcM. Dual-Target CAR-Ts With on- And Off-Tumour Activity May Override Immune Suppression in Solid Cancers: A Mathematical Proof of Concept. Cancers. 2021;13(4):703.

Liao Q, Mao Y, He H, Ding X, Zhang X, Xu J. PD-L1 Chimeric Costimulatory Receptor Improves the Efficacy of CAR-T Cells for PD-L1-positive Solid Tumors and Reduces Toxicity in Vivo. Biomarker Research. 2020;8(1).

Park AK, Fong Y, Kim S, Yang J, Murad JP, Lü J, et al. Effective Combination Immunotherapy Using Oncolytic Viruses to Deliver CAR Targets to Solid Tumors. Science Translational Medicine. 2020;12(559).

Xu N, Wu D, Gao J, Jiang H, Li Q, Bao S, et al. The effect of tumor vascular remodeling and immune microenvironment activation induced by radiotherapy: quantitative evaluation with magnetic resonance/photoacoustic dual-modality imaging. Quant Imaging Med Surg. 2023;13(10):6555-70.

Amit U. Proton Radiation Boosts the Efficacy of Mesothelin-Targeting Chimeric Antigen Receptor T Cell Therapy in Pancreatic Cancer. Proceedings of the National Academy of Sciences. 2024;121(31).

Saifi O, Breen WG, Lester SC, Rule WG, Stish BJ, Rosenthal A, et al. Don't Put the CART Before the Horse: The Role of Radiation Therapy in Peri-CAR T-cell Therapy for Aggressive B-cell Non-Hodgkin Lymphoma. Int J Radiat Oncol Biol Phys. 2023;116(5):999-1007.

Wang AX, Ong XJ, D’Souza C, Neeson PJ, Zhu JJ. Combining Chemotherapy With CAR-T Cell Therapy in Treating Solid Tumors. Frontiers in Immunology. 2023;14.

Xia Z, Tian M, Cheng Y, Yi W, Du Z, Li T, et al. Preclinical evaluation of cyclophosphamide and fludarabine combined with CD19 CAR-T in the treatment of B-cell hematologic malignancies in vivo. Oncol Res. 2024;32(6):1109-18.

Yang M, Wang L, Ni M, Neuber B, Wang S, Gong W, et al. Pre-Sensitization of Malignant B Cells Through Venetoclax Significantly Improves the Cytotoxic Efficacy of CD19.CAR-T Cells. Frontiers in Immunology. 2020;11.

Gargett T, Yu W, Dotti G, Yvon E, Christo SN, Hayball JD, et al. GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but Can Be Protected From Activation-Induced Cell Death by PD-1 Blockade. Molecular Therapy. 2016;24(6):1135-49.

Chen X, Yang S, Li S, Qu Y, Wang HY, Liu J, et al. Secretion of bispecific protein of anti-PD-1 fused with TGF-beta trap enhances antitumor efficacy of CAR-T cell therapy. Mol Ther Oncolytics. 2021;21:144-57.

Mu J, Liu M, Wang J, Meng J, Zhang R, Jiang Y, et al. Successful Treatment of Second-Time CAR-T 19 Therapy After Failure of First-Time CAR-T 19 and Ibrutinib Therapy in Relapsed Mantle Cell Lymphoma. Advances in Clinical and Experimental Medicine. 2022;31(3):327-35.

Zhao G, Wei R, Feng L, Wu Y, He F, Xiao M, et al. Lenalidomide Enhances the Efficacy of Anti-Bcma CAR-T Treatment in Relapsed/Refractory Multiple Myeloma: A Case Report and Revies of the Literature. Cancer Immunology Immunotherapy. 2021;71(1):39-44.

Chong EA, Melenhorst JJ, Lacey SF, Ambrose DE, Gonzalez V, Levine BL, et al. PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR. Blood. 2017;129(8):1039-41.

Armand P, Rodig S, Melnichenko V, Thieblemont C, Bouabdallah K, Tumyan G, et al. Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma. J Clin Oncol. 2019;37(34):3291-9.

Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018;24(5):563-71.

Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest. 2016;126(6):2123-38.

Bachanova V, Perales MA, Abramson JS. Modern management of relapsed and refractory aggressive B-cell lymphoma: A perspective on the current treatment landscape and patient selection for CAR T-cell therapy. Blood Rev. 2020;40:100640.

Yu L, Zou R, He J, Qu C. Role of radiation in chimeric antigen receptor T-cell therapy for patients with relapsed/refractory non-Hodgkin lymphoma: Current studies and future prospects. Crit Rev Oncol Hematol. 2024;199:104390.

Majhail NS, Weisdorf DJ, Defor TE, Miller JS, McGlave PB, Slungaard A, et al. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma. Biol Blood Marrow Transplant. 2006;12(10):1065-72.

June CH, O'Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361-5.

Scholler J, Brady TL, Binder-Scholl G, Hwang WT, Plesa G, Hege KM, et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med. 2012;4(132):132ra53.

Zhang X, Zhang H, Lan H, Wu J, Xiao Y. CAR-T Cell Therapy in Multiple Myeloma: Current Limitations and Potential Strategies. Frontiers in Immunology. 2023;14.

Zhu H. Three Cases of Late‐onset post CAR‐T Therapy Isolated CNS Relapse in R/R Large B‐cell Lymphoma. European Journal of Haematology. 2023;112(2):310-3.

Chan JD, Scheffler CM, Munoz I, Sek K, Lee JN, Huang YK, et al. FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy. Nature. 2024;629(8010):201-10.

Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol. 2023;20(6):359-71.

Gupta S, Kohorst M, Alkhateeb HB. Determinants of outcomes and advances in CD19-directed chimeric antigen receptor therapy for B-cell acute lymphoblastic leukemia. Eur J Haematol. 2024;112(1):51-63.

Sanchez-Moreno I, Lasarte-Cia A, Martin-Otal C, Casares N, Navarro F, Gorraiz M, et al. Tethered IL15-IL15Ralpha augments antitumor activity of CD19 CAR-T cells but displays long-term toxicity in an immunocompetent lymphoma mouse model. J Immunother Cancer. 2024;12(7).

Yin X, He L, Guo Z. T‐cell Exhaustion in CAR‐T‐cell Therapy and Strategies to Overcome It. Immunology. 2023;169(4):400-11.

Aparicio-Perez C, Carmona M, Benabdellah K, Herrera C. Failure of ALL recognition by CAR T cells: a review of CD 19-negative relapses after anti-CD 19 CAR-T treatment in B-ALL. Front Immunol. 2023;14:1165870.

Wachsmann TLA, Meeuwsen MH, Remst DFG, Buchner K, Wouters AK, Hagedoorn RS, et al. Combining BCMA-targeting CAR T cells with TCR-engineered T-cell therapy to prevent immune escape of multiple myeloma. Blood Adv. 2023;7(20):6178-83.

Si S, Teachey DT. Spotlight on Tocilizumab in the Treatment of CAR-T-Cell-Induced Cytokine Release Syndrome: Clinical Evidence to Date. Ther Clin Risk Manag. 2020;16:705-14.

Li X, Liu M, Mou N, Yang Z, Wang J, Mu J, et al. Efficacy and Safety of Humanized CD19 CAR‑T as a Salvage Therapy for Recurrent CNSL of B‑ALL Following Murine CD19 CAR‑T Cell Therapy. Oncology Letters. 2021;22(5).

Miao L, Zhang J, Zhang Z, Wang S, Tang F, Teng M, et al. A Bibliometric and Knowledge-Map Analysis of CAR-T Cells From 2009 to 2021. Frontiers in Immunology. 2022;13.

Wang Y, Yu W, Zhu J, Wang J, Xia K, Liang C, et al. Anti-Cd166/4-1bb Chimeric Antigen Receptor T Cell Therapy for the Treatment of Osteosarcoma. Journal of Experimental & Clinical Cancer Research. 2019;38(1).

Liang Z, Dong J, Yang N, Li S-D, Yang Z, Huang R, et al. Tandem CAR-T Cells Targeting FOLR1 and MSLN Enhance the Antitumor Effects in Ovarian Cancer. International Journal of Biological Sciences. 2021;17(15):4365-76.

Li F, Zhao S, Wei C, Hu Y, Xu T, Xin X, et al. Development of Nectin4/FAP-targeted CAR-T Cells Secreting IL-7, CCL19, and IL-12 for Malignant Solid Tumors. Frontiers in Immunology. 2022;13.

He J, Munir F, Ragoonanan D, Zaky W, Khazal SJ, Tewari P, et al. Combining CAR T Cell Therapy and Oncolytic Virotherapy for Pediatric Solid Tumors: A Promising Option. Immuno [Internet]. 2023; 3(1):[37-56 pp.].

Fang L. Recombinant Oncolytic Adenovirus Armed With CCL5, IL-12, and IFN-γ Promotes CAR-T Infiltration and Proliferation in Vivo to Eradicate Local and Distal Tumors. Cell Death Discovery. 2023;9(1).

Rodríguez-García A, Palazón A, Noguera-Ortega E, Powell DJ, Guedan S. CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape. Frontiers in Immunology. 2020;11.

Zhang PF, Xie D. Targeting the gut microbiota to enhance the antitumor efficacy and attenuate the toxicity of CAR-T cell therapy: a new hope? Front Immunol. 2024;15:1362133.

Zou B. Biomarkers for Predicting Efficacy of Chimeric Antigen Receptor T Cell Therapy and Their Detection Methods. Ilabmed. 2024;2(1):14-26.

Nakamura N, Jo T, Arai Y, Kitawaki T, Nishikori M, Mizumoto C, et al. Utilizing red blood cell distribution width (RDW) as a reliable biomarker to predict treatment effects after chimeric antigen receptor T cell therapy. Clin Exp Med. 2024;24(1):105.

Li D, Xu Q, Hu Y, Wang W, Xie S, Zhao C, et al. Tumor-intrinsic CD21 expression impacts the response of B-cell malignancy cells to CD19-CAR-T cells. J Leukoc Biol. 2022;112(4):913-8.

Pomeroy AE, Palmer AC. Abstract 6549: Mechanistic models of tumor and patient heterogeneity explain and predict clinical outcomes of large B-cell lymphoma (LBCL) treatment. Cancer Research. 2024;84(6_Supplement):6549-.

Bethge WA, Martus P, Schmitt M, Holtick U, Subklewe M, von Tresckow B, et al. GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany. Blood. 2022;140(4):349-58.

Stadelmann. Significant Progress in CAR T-Cell Therapy for Difficult-to-Treat Hematologic Malignancies. Healthbook Times Oncology Hematology. 2022(13).

Iacoboni G, Villacampa G, Martinez-Cibrian N, Bailen R, Lopez Corral L, Sanchez JM, et al. Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma. Cancer Med. 2021;10(10):3214-23.